NJ State Employees Deferred Compensation Plan’s Sarepta Therapeutics SRPT Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,900	Closed	-$440K	–	443
2025 Q1	$440K	Hold	6,900	–	–	0.06%	303
2024 Q4	$839K	Hold	6,900	–	–	0.1%	195
2024 Q3	$862K	Hold	6,900	–	–	0.1%	200
2024 Q2	$1.09M	Hold	6,900	–	–	0.14%	157
2024 Q1	$893K	Hold	6,900	–	–	0.11%	187
2023 Q4	$665K	Hold	6,900	–	–	0.09%	230
2023 Q3	$836K	Hold	6,900	–	–	0.13%	177
2023 Q2	$790K	Hold	6,900	–	–	0.11%	196
2023 Q1	$951K	Hold	6,900	–	–	0.15%	164
2022 Q4	$894K	Hold	6,900	–	–	0.14%	166
2022 Q3	$763K	Buy	+6,900	New	+$695K	0.13%	174
2019 Q3	–	Sell	-3,000	Closed	-$456K	–	551
2019 Q2	$456K	Buy	3,000 +1,000	+50%	+$122K	0.08%	299
2019 Q1	$238K	Sell	2,000 -1,000	-33%	-$129K	0.04%	485
2018 Q4	$327K	Hold	3,000	–	–	0.07%	348
2018 Q3	$485K	Buy	3,000 +1,000	+50%	+$137K	0.08%	330
2018 Q2	$264K	Buy	+2,000	New	+$189K	0.05%	446

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's SRPT Position: Q2 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 6,900 shares — an estimated $440K sold.

NJ State Employees Deferred Compensation Plan first reported a position in SRPT in Q2 2018 and held it in 16 quarters. The position peaked at $1.09M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 6,900 Sarepta Therapeutics shares in Q2 2025, an estimated $440K.
NJ State Employees Deferred Compensation Plan first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 16 quarters.
NJ State Employees Deferred Compensation Plan's Sarepta Therapeutics position peaked at $1.09M in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q2 2025, filed 5 Aug 2025.